TACSTD2 and hypopharyngeal carcinoma: The expression of TROP2 was evaluated in 3 HNSCC cancer cell lines: Fadu (hypopharyngeal carcinoma), SCC-9 (tongue carcinoma), and SCC-22 (hypopharyngeal carcinoma) compared with that of the normal oral epithelial cell line NOE.